دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
The frontiers of vascular biology: single-cell technologies, small non-coding RNA therapeutics, and new pharmacological targets
Filippo Crea
doi : 10.1093/eurheartj/ehac631
European Heart Journal, Volume 43, Issue 43, 14 November 2022, Pages 4521–4524
Artificial intelligence in proteomics: new frontiers from risk prediction to treatment?
Matthias Unterhuber, Karl-Patrik Kresoja, Philipp Lurz, Holger Thiele
doi : 10.1093/eurheartj/ehac391
European Heart Journal, Volume 43, Issue 43, 14 November 2022, Pages 4525–4527
Panvascular medicine: an emerging discipline focusing on atherosclerotic diseases
Xiang Zhou, Linchan Yu, Yiheng Zhao, Junbo Ge
doi : 10.1093/eurheartj/ehac448
European Heart Journal, Volume 43, Issue 43, 14 November 2022, Pages 4528–4531
Antithrombotic therapy in patients undergoing transcatheter aortic valve replacement
Yaling Han
doi : 10.1093/eurheartj/ehac290
European Heart Journal, Volume 43, Issue 43, 14 November 2022, Pages 4532–4533
A SECURE polypill as a strategy at the heart of secondary prevention
Giovanna Liuzzo, Carlo Patrono
doi : 10.1093/eurheartj/ehac518
European Heart Journal, Volume 43, Issue 43, 14 November 2022, Pages 4534–4535
Single-cell technologies to decipher cardiovascular diseases
Wesley Tyler Abplanalp, Nathan Tucker, Stefanie Dimmeler
doi : 10.1093/eurheartj/ehac095
European Heart Journal, Volume 43, Issue 43, 14 November 2022, Pages 4536–4547
Cardiovascular disease remains the leading cause of death worldwide. A deeper understanding of the multicellular composition and molecular processes may help to identify novel therapeutic strategies.
Small non-coding RNA therapeutics for cardiovascular disease
Ajay M Shah, Mauro Giacca
doi : 10.1093/eurheartj/ehac463
European Heart Journal, Volume 43, Issue 43, 14 November 2022, Pages 4548–4561
Novel bio-therapeutic agents that harness the properties of small, non-coding nucleic acids hold great promise for clinical applications. These include antisense oligonucleotides that inhibit messenger RNAs, microRNAs (miRNAs), or long non-coding RNAs; positive effectors of the miRNA pathway (short interfering RNAs and miRNA mimics); or small RNAs that target proteins (i.e. aptamers).
The epigenetic enzyme DOT1L orchestrates vascular smooth muscle cell–monocyte crosstalk and protects against atherosclerosis via the NF-κB pathway
Floriana Maria Farina, Simone Serio, Ignacio Fernando Hall, Stefania Zani, Giada Andrea Cassanmagnago, Montserrat Climent, Efrem Civilini, Gianluigi Condorelli, Manuela Quintavalle, Leonardo Elia
doi : 10.1093/eurheartj/ehac097
European Heart Journal, Volume 43, Issue 43, 14 November 2022, Pages 4562–4576
Histone H3 dimethylation at lysine 79 is a key epigenetic mark uniquely induced by methyltransferase disruptor of telomeric silencing 1-like (DOT1L). We aimed to determine whether DOT1L modulates vascular smooth muscle cell (VSMC) phenotype and how it might affect atherosclerosis in vitro and in vivo, unravelling the related mechanism.
Orchestration of vascular smooth muscle cell plasticity using epigenetic therapy
Thomas Thum
doi : 10.1093/eurheartj/ehac200
European Heart Journal, Volume 43, Issue 43, 14 November 2022, Pages 4577–4578
Exerkine fibronectin type-III domain-containing protein 5/irisin-enriched extracellular vesicles delay vascular ageing by increasing SIRT6 stability
Chen Chi, Hui Fu, Yong-Hua Li, Guo-Yan Zhang, Fei-Yan Zeng, Qing-Xin Ji, Qi-Rui Shen, Xu-Jie Wang, Zi-Chen Li, Can-Can Zhou, Di-Yang Sun, Jiang-Tao Fu, Wen-Bin Wu, Ping-Ping Zhang, Jia-Bao Zhang, Jian Liu, Fu-Ming Shen, Dong-Jie Li, Pei Wang
doi : 10.1093/eurheartj/ehac431
European Heart Journal, Volume 43, Issue 43, 14 November 2022, Pages 4579–4595
Exercise confers protection against cardiovascular ageing, but the mechanisms remain largely unknown. This study sought to investigate the role of fibronectin type-III domain-containing protein 5 (FNDC5)/irisin, an exercise-associated hormone, in vascular ageing.
Fndc5/irisin-enriched extracellular vesicles: a new hormonal relay in the regular race against vascular ageing
Vincenzo Lionetti, Lucio Barile
doi : 10.1093/eurheartj/ehac517
European Heart Journal, Volume 43, Issue 43, 14 November 2022, Pages 4596–4598
Is a genotype-guided therapy the optimal strategy to personalize anti-thrombotic management in patients with acute coronary syndrome?
Wout W A van den Broek, Jurriën M ten Berg
doi : 10.1093/eurheartj/ehac219
European Heart Journal, Volume 43, Issue 43, 14 November 2022, Pages 4599–4600
A dangling right heart tumour
Jan Van Keer, Céline Deschepper, Jerrold Spapen
doi : 10.1093/eurheartj/ehac501
European Heart Journal, Volume 43, Issue 43, 14 November 2022, Page 4601,
A rare case of native aortic valve thrombosis after radiofrequency ablation
Juan Xia, Yanling Xue, Xiaojing Ma
doi : 10.1093/eurheartj/ehac505
European Heart Journal, Volume 43, Issue 43, 14 November 2022, Page 4602
